ASPG and acute lymphoblastic leukemia: The patient was treated according to the high risk protocol of the ALL-BFM-2000 trial with prednisone, vincristine, daunorubicin, L-asparaginase, cyclophosphamide, high dose methotrexate, cytarabine, mercaptopurine, thioguanine, and etoposide.